Envarsus: first tablet presentation of tacrolimus

Chiesi has launched Envarsus, the first prolonged-release tablet formulation of tacrolimus. The once-daily tablets are available in 750 microgram, 1mg and 4mg strengths.

Like other oral tacrolimus products, Envarsus should be prescribed by brand name.
Like other oral tacrolimus products, Envarsus should be prescribed by brand name.

Further information
View Envarsus drug record
Manufacturer: Chiesi
MHRA advice on oral tacrolimus

Envarsus is licensed for the prevention of transplant rejection in kidney or liver allograft recipients and the treatment of allograft rejection resistant to other immunosuppressants.

Different formulations of tacrolimus are not interchangeable without careful monitoring. Healthcare professionals should be aware of the different bioavailabilities of the available oral formulations and take care to prescribe and dispense the correct product.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases